Obstetrics and Gynecology
Preventative Care in Gynecology
- Preventative care in gynecology
- 1. What every clinician should know
2. What is the evidence for specific management and treatment recommendations?
Preventative care in gynecology
1. What every clinician should know
Periodic assessments provide an opportunity for physicians to screen, evaluate, and counsel women about preventive care. Age and risk factors should serve as a guide for offering appropriate screening tests or immunizations. Physicians can use this encounter to identify women at risk for high-risk conditions and to assist their patients to receive appropriate medical care.
Certain behaviors span all age groups and should be addressed at every visit. Exercise, healthy diet, safe sexual practices, and injury prevention should be evaluated and reinforced. Patients should be asked about tobacco use, alcohol consumption, drug abuse (either prescription or illegal drugs), and psychosocial interactions.
The focus of this chapter is on screening tests and interventions for the general population. Cervical cancer screening and sexually transmitted infection screening is discussed in other chapters. Recommendations for this chapter are based upon the American College of Obstetricians and Gynecologists' Committee Opinion "Primary and Preventive Care: Periodic Assessments."
Women should receive clinical breast exams every 1-3 years beginning at age 19. The average risk woman should begin screening mammograms at age 40. She should receive a mammogram once every one to two years. Starting at age 50, women should receive mammograms annually. For average risk women, screening with MRI is not recommended.
The Gail Model can be used to estimate a woman's breast cancer risk. (www.cancer.gov/bcrisktool/). A lifetime breast cancer risk of below 15% is considered average risk. Women with a lifetime risk of above 25% are considered at highest risk and should be referred to a breast specialist to determine appropriate screening intervals. There are no specific guidelines for women at intermediate risk (between 15% and 25%) of breast cancer. Currently, recommendations for women at intermediate risk are the same as for women at average risk.
Bone density screening
The average risk woman should begin bone mineral density testing at age 65. In women with no risk factors for osteoporosis, bone mineral density testing should be repeated approximately every 3 to 5 years.
Bone mineral density testing may be performed on postmenopausal women younger than 65 years if they have one more of the following risk factors:
family history of osteoporosis
low body mass index
early menopause (younger than 45 years)
prolonged premenopausal amenorrhea
long-term low calcium intake
high risk for falls
All postmenopausal women with fractures should have bone mineral density testing. High risk women with ongoing factors which may increase bone loss should be screened no more frequently than every 2 years.
Various medical conditions or treatments may place women at greater risk for osteopopenia or osteoporosis and should be considered on a case by case basis. Women diagnosed with osteopenia or low bone mass should optimize their daily intake of calcium and vitamin D. Physicians should encourage these women to undertake regular weight bearing exercise, smoking cessation, and fall prevention strategies.
Pharmacologic treatment for osteopenia/osteoporosis is recommended for:
Postmenopausal women with a fracture
Postmenopausal women with no risk factors, but a T score of less than -2 (osteoporosis)
Postmenopausal women with risk factors, and a T score of less than -1.5 (severe osteopenia)
Colon cancer screening
The average risk woman should begin colorectal cancer screening at age 50 and continue until age 75.
Acceptable screening tests include:
Colonoscopy performed every 10 years
Flexible sigmoidoscopy performed every 5 years
Double contrast barium enema performed every 5 years
Fecal occult blood test on 3 consecutive samples of stool performed yearly
Fecal occult blood testing performed on digital rectal examination during an office visit is insufficient for detection of colorectal cancer. Multiple advisory boards recommend that a single collection fecal occult blood testing should not be performed.
High risk patients include:
Those with a history of colorectal cancer or adenomatous polyps in a first-degree relative younger than age 60
Those with a family history of familial adenomatous polyposis or hereditary nonpolyposis colon cancer
Those with a personal history of colorectal cancer or adenomatous polyps
Patients with inflammatory bowel disease
Those with chronic ulcerative colitis
Patients with Crohn's disease
Screening for high risk patients should begin at age 40. If the risk factor is a first degree relative with cancer, screening should begin 10 years before the age of diagnosis of the family member.
Identifying chronic medical conditions in asymptomatic patients
High blood pressure is defined at a systolic blood pressure of 140 mm Hg or higher or a diastolic blood pressure of 90 mm Hg or higher. Hypertension is diagnosed after 2 or more elevated readings obtained at 2 or more visits over a period of several weeks. Women with a systolic blood pressure below 120 mm Hg and a diastolic blood pressure below 80 mm Hg should be screened every 2 years. Women with a systolic blood pressure between 120-130 mm Hg and a diastolic blood pressure between 80-89 mm Hg should be screened every year.
For those of average risk, a fasting glucose test every 3 years after age 45 is recommended. For patients with any of the below risk factors, screen as long as risk factor persists. Alternate screening tests include the two hour glucose tolerance test and glycolated hemoglobin (A1c).
Patients at high risk to develop diabetes include:
Overweight patients (BMI > 25)
Those with a family history significant for diabetes
Those of a high risk race or ethnicity (African-American, Latina, Native American, Pacific Islander)
Patients with hypertension, dyslipidemia, or a history of vascular disease
Conditions among women which may predispose them to diabetes include history of gestational diabetes, giving birth to an infant weighing greater than 9 lbs, and polycystic ovarian syndrome.
For those of average risk, it is recommended to have a lipid profile assessment every five years beginning at age 45. For those of high risk, a lipid profile assessment every five years is recommended beginning at age 20. The preferred screening test is total cholesterol and HDL on fasting or non-fasting samples.
Patients at increased risk for cardiovascular events who need earlier screening for cholesterol include patients with:
Obesity (BMI >30)
Previous personal history of CHD or non-coronary atherosclerosis
Family history of cardiovascular disease before age 50 in males or before age 60 in females.
Thyroid-stimulating hormone testing should be done every five years beginning at age 50 for those of average risk. Subtle signs of thyroid dysfunction in high risk populations should be evaluated.
High risk populations include:
Women with Down syndrome
Women with high levels of radiation exposure
A strong family history of thyroid disease or history of autoimmune disease
These patients should be screened if indicated by symptoms.
Many adults are at risk for vaccine preventable diseases. Since the obstetrician-gynecologist may be a woman's primary care physician, it is important to assess her vaccination status. Influenza is recommended for all healthy women annually and recommended for all pregnant and breastfeeding women. All women who have not previously received Tetanus, diphtheria, pertussis (Tdap) vaccine should receive it regardless of the timing of their last Td vaccination. All postpartum women should receive the Tdap vaccine postpartum. Women should receive Td boosters every 10 years.
Women who have no evidence of varicella immunity should receive the varicella vaccine. Varicella immunity may be documented by a known history of varicella or by laboratory testing. Women aged 9-26 years should receive the HPV vaccination series Zoster vaccination is recommended for all women 60 years or older regardless of history of shingles. All women over 65 years of age should receive the pneumococcus vaccine.
Adults with chronic medical conditions, workplace exposures, or a variety of lifestyle or behavioral factors may be eligible for vaccination at different ages than the recommendations above. Additionally, some women should receive the meningococcal, Hepatitis A, and Hepatitis B vaccine. Recommendations for these groups are available from the CDC.
2. What is the evidence for specific management and treatment recommendations?
"American College of Obstetricians and Gynecologists". Obstet Gynecol. vol. 117. 2011. pp. 1008-15.
"Recommendations for Adults. U.S". Preventative Services Task Force.. http://www.uspreventativeservicestaskforce.org/adultrec.htm.
"Immunizations for Women". The American College of Gynecologists and Obstetricians. http://www.immunizationforwomen.org.
"Adult Immunization Schedules. Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention.". http://www.cdc.gov/vaccines/recs/schedules.
Copyright © 2017, 2014 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Behavior Pain Assessment Tool Measures Pain In Patients Who Cannot Communicate Verbally
- Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Updated ASTRO Guideline Bolsters Safety, Efficacy of Palliative RT for Bone Metastases
- Thyroid Cancer Incidence Increasing Among Younger, Hispanic, African American Populations
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Recommendations Against Contralateral Prophylactic Mastectomy Not Tied to Patient Satisfaction
- Self-efficacy Level Predictive of Likelihood to Follow Through With Colorectal Cancer Screening
- Chronic Myeloproliferative Neoplasms Treatment (Fact Sheet)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|